Loading...

Cost-effectiveness of amivantamab plus lazertinib and osimertinib plus chemotherapy versus osimertinib monotherapy for first-line EGFR-mutated advanced non-small cell lung cancer: an updated analysis - Figshare | NLM Dataset Catalog